E S G P E R F O R M A N C E D A T A

ESG Performance Data 2021

We assess the effectiveness of our sustainability activities by monitoring key performance indicators (KPIs). The KPIs below give an indication of our performance in environment, social, and governance (ESG) topics over the past five years. For more information, please refer to our Non-FinancialGroup Report.

This index is currently only available in English.

2021

2020

2019

2018

2017

PATIENTS

Number of patients treated

Number of dialysis clinics worldwide

Number of dialysis treatments (millions)

Share of dialysis product market (%)

Share of dialysis patients treated worldwide (%)

North America (%)

Europe, Middle East and Africa (%)

Asia-Pacific (%)

Latin America (%)

345,425 1

346,553

345,096

333,331

320,960

4,171

4,092

3,994

3,928

3,752

52.9

53.6

52.1

50.0

48.3

36

36

36

35

35

9

9

10

10

10

30

30

31

31

31

8

8

8

8

8

2

2

2

2

2

12

12

12

11

11

  • Figures marked with a are included in the Annual Report, which has been subject to a third-party assessment.

ESG Performance Data | Page 2 out of 12

2021

2020

2019

2018

2017

QUALITY OF CARE AND PATIENT SATISFACTION

Number of key partnerships with academia, research

> 60

> 40

n/a2

n/a

n/a

institutes, and peers

Net Promoter Score

71

67

n/a

n/a

n/a

Patients who would highly recommend our services (%)

78

75

n/a

n/a

n/a

Coverage rate of patient experience survey (%)

91

78

n/a

n/a

n/a

Response rate of patient experience survey (%)

75

76

n/a

n/a

n/a

Global hospitalization rate per patient in days

10.7

n/a

n/a

n/a

n/a

PRODUCT QUALITY AND SAFETY

Number of production sites worldwide

42

44

45

42

41

Operations covered by quality management systems (%)3

98

98

n/a

n/a

n/a

Number of product improvements to dialysis machines,

> 2,000

> 440

n/a

n/a

n/a

dialyzers, filters, and solution products4

Audit score5

0.1

0.2

0.2

0.3

n/a

INNOVATION

R&D expenditures (thousand €)

220,782

193,774

168,028

114,074

110,997

R&D expenditures as a percentage of health care product

6

5

5

3

3

revenue (%)

Number of patents

10,048

11,223

10,658

9,152

8,396

Number of patent families

1,622

1,626

1,518

~1,340

1,253

  • n/a = not available.
  • Includes ISO 9001/13485, Good Manufacturing Practice (GMP)/ Current Good Manufacturing Practice (cGMP), and Medical Device Single Audit Program (MDSAP).
    4 In 2020, this figure only included the product improvements made to dialysis machines.
    5 The audit score measures our performance in certification audits and indicates the ratio of major and critical findings to the number of external audits.

ESG Performance Data 2021 | Page 3 out of 12

2021

2020

2019

2018

2017

Number of new patent families produced

103

135

163

126

126

EMPLOYEES

Number of employees (headcount)

Number of employees (FTE)

EMPLOYEES PER REGION6

North America (%)

Latin America (%)

Europe, Middle East and Africa (incl. Germany) (%)

Germany (%)

Asia-Pacific (%)

Corporate (%)

EMPLOYEES PER FUNCTIONAL AREA6

Production and services (%)

Administration (%)

Sales and marketing (%)

Research and development (%)

INCLUSION AND DIVERSITY

Average age (years)

Employees under 30 years (%)

130,251

133,129

128,300

120,328

121,245

122,909

125,364

120,659

112,658

114,000

49

50

50

50

51

10

9

9

8

8

16

17

17

17

17

6

6

6

6

5

10

10

10

10

9

15

14

14

15

15

85

86

86

86

87

10

10

10

10

9

4

3

3

3

3

1

1

1

1

1

42

42

41

41

42

16

17

18

16

18

  • Employees calculated as full-time equivalents (FTEs).

ESG Performance Data 2021 | Page 4 out of 12

2021

2020

2019

2018

2017

Employees between 30 and 50 years (%)

58

58

56

57

56

Employees over 50 years (%)

26

25

26

27

26

Female managers (%)7

59

n/a

n/a

n/a

n/a

Female employees in entire company (%)

69

69

69

69

69

Female employees in North America (%)

72

71

72

72

70

Female employees in Europe, Middle East and Africa (%)

67

66

66

67

67

Female employees in Latin America (%)

67

66

65

67

68

Female employees in Asia-Pacific (%)

65

65

64

65

65

Management Board members between 30 and 50 years (%)

12.5

12.5

14.3

14.3

28.6

Management Board members over 50 years (%)

87.5

87.5

85.7

85.7

71.4

Share of women in the Management Board (%)

25

25

29

14

0

Supervisory Board members between 30 and 50 years (%)

0

0

16.7

0

16.7

Supervisory Board members over 50 years (%)

100

100

83.3

100

83.3

Share of women in the Supervisory Board (%)

33

33

33

33

33

Women at first management level (%)8

18

18

23

21

19

Women at second management level (%)9

28

28

30

27

28

Female Long-Term Incentive Plan (LTIP) participants (%)

34

34

34

33

33

Non-Germans within the Management Board (%)

75

75

71

71

86

  • Managers are defined as employees with direct reports. The figure is as of March 31, 2021.
  • Figures from 2017 to 2019 include all employees that participate in our Long-Term Incentive Plan (LTIP) and report directly to a Management Board member. For 2020 and 2021, figures include all managers in respective leadership positions according to our new global job evaluation system.
    9 Figures from 2017 to 2019 include all employees that participate in our Long-Term Incentive Plan (LTIP) and report directly to a first-level leader. For 2020 and 2021, figures include all managers in respective leadership positions according to our new global job evaluation system.

ESG Performance Data 2021 | Page 5 out of 12

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 31 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2022 16:00:01 UTC.